Kirin Nine-Month Net Profit Jumps 43% to ¥147.4 Billion as Kyowa Kirin Profit Surges 44% and Four Roses Sale Adds Gain

Pharma and health science drive growth

Kirin Holdings Company, Limited (TSE: 2503) reported consolidated results under IFRS for the first nine months of FY12/2026, January 1 to September 30, 2026, on November 11, 2026. Pharmaceuticals, centred on Kyowa Kirin, lifted segment business profit 44.2% to ¥88,067 million on revenue up 10.2%. Health Science, which includes Fancl and Blackmores, rose 34.4% to ¥17,030 million. Alcoholic Beverages, covering Kirin Brewery, Lion in Oceania and New Belgium in North America, rose 5.2% to ¥95,629 million, while Non-Alcoholic Beverages, including Kirin Beverage and Coca-Cola Beverages Northeast in the U.S., slipped 1.7% to ¥51,769 million despite revenue up 6.2%.

Kirin sold all of its interest in Four Roses Distillery during the period and booked a ¥29,033 million gain on the loss of control, taking other operating income to ¥46,998 million. Operating profit rose 36.2% to ¥197,264 million and profit before tax 34.4% to ¥224,861 million. Basic earnings per share rose to ¥183.91 from ¥126.95. Total assets fell 4.6% to ¥3,331,804 million as receivables and inventories declined, and the equity ratio rose to 40.1%.

Guidance and dividend unchanged

Kirin kept its FY12/2026 forecast of revenue of ¥2,480,000 million (+1.9%), business profit of ¥253,000 million (+0.5%) and net profit attributable to owners of ¥160,000 million (+8.4%). The nine months have already delivered 79.5% of the business profit target and 92.1% of the net profit target. The dividend forecast is ¥76 (¥38 interim, ¥38 year-end), up from ¥74.

JapanStockPulse provides informational content only and does not constitute investment advice. Figures are taken from the company's published earnings short report and may be subject to subsequent revision.